XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net loss attributable to Oncocyte Corporation $ (8,333) $ (8,300) $ (5,300) $ (18,591)
Dividend on Series A redeemable convertible preferred stock (76) (29) (166) (29)
Accretion of Series A redeemable convertible preferred stock (117) (43) (257) (43)
Deemed dividend on Series A redeemable convertible preferred stock (118) (118)
Net loss attributable to common stockholders - Basic (8,644) (8,372) (5,841) (18,663)
Net income (loss) attributable to common stockholders - diluted $ (8,644) $ (8,372) $ (5,841) $ (18,663)
Weighted average number of shares outstanding, basic 8,090 5,652 7,030 5,135
Weighted average number of shares outstanding, diluted 8,090 5,652 7,030 5,135
Basic net loss per common share $ (1.07) $ (1.48) $ (0.83) $ (3.63)
Earnings Per Share, diluted $ (1.07) $ (1.48) $ (0.83) $ (3.63)
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 1,315,000 1,582,000 1,384,000 1,508,000
Equity Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 483,000 731,000 549,000 657,000
Restricted Stock Units (RSUs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 7,000 10,000
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 820,000 845,000 820,000 845,000
Series A Redeemable Convertible Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share 5,000 6,000 5,000 6,000